---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-24-000079"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:44:21.010279+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Centessa Q1 net loss $38M; initiates ORX750 Phase 1, cash runway into mid-2026

## Summary
- Net loss of $38.0M, improved from $50.7M in Q1 2023; R&D expense $22.7M vs $32.8M.
- Cash, equivalents, and short-term investments $230.2M as of March 31, plus $107.2M net from April/May ADS offering.
- Phase 1 first-in-human trial of ORX750 (narcolepsy) initiated; proof-of-concept data expected 2H 2024.
- SerpinPC registrational PRESent-2 interim analysis planned for 2024; Part 1 data to be shared late 2024/early 2025.
- LB101 (PD-L1xCD47) Phase 1/2a for solid tumors ongoing.

## SEC filing metadata
- accession: 0001847903-24-000079
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/0001847903-24-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/cnta-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-24-000079
- JSON: https://secwatch.observer/filing/0001847903-24-000079.json
- Plain text: https://secwatch.observer/filing/0001847903-24-000079.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2024 results: net income $38.0 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: $38.0 million
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000079/0001847903-24-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.